Semler Scientific Comments on CMS Risk Adjustment Changes in the 2024 Medicare Advantage and Part D Final Rate Announcement

Key Facts

, /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, commented on the recent Centers for Medicare and Medicaid Services (CMS) 2024 Medicare Advantage and Part D Final Rate Announcement.
Semler Scientific believes that the paradigm of earlier diagnosis and intervention will become the standard of care in managing patients with PAD and/or HD.
About Semler Scientific, Inc.: Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers.
Such forward-looking statements are subject to a number of risks and uncertainties that could cause forward looking statements to differ materially from those discussed herein, such as whether or not QuantaFlo can provide value to customers and whether or not customers will continue to prioritize screening asymptomatic patients, along with those risk factors detailed in Semler Scientific's filings with the Securities and Exchange Commission.